A Phase 1, Randomized, Subject- and Investigator-blinded, Sponsor-unblinded, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of ASP7962, Including a Food-effect Evaluation in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Aug 2014
Price : $35 *
At a glance
- Drugs ASP 7962 (Primary)
- Indications Back pain; Osteoarthritis
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 10 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 09 May 2014 Planned End Date changed from 1 Apr 2014 to 1 May 2014, as per ClinicalTrials.gov record.
- 26 Mar 2014 Planned End Date changed from 1 Feb 2014 to 1 Apr 2014, as per ClinicalTrials.gov record.